Our ClinicalTrials.gov based review of ongoing studies revealed six studies investigating the effects of GLP-1-RA and SGLT-2 inhibitors with DM II in the post-stroke setting (see Online Supplement Supplementary Table 1). This evidence concerns the gene SLC5A2 and stroke disorder.